Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B

Fatih ERBEY1, Emine KOCABAŞ2, Ibrahim BAYRAM1, Süreyya SOYUPAK3, Derya GÜMÜRDÜLÜ4, Atilla TANYELİ1

1 Çukurova Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Onkoloji Bilim Dalı, Adana, Turkey,
2 Çukurova Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk İnfeksiyon Bilim Dalı, Adana, Turkey,
3 Çukurova Üniversitesi Tıp Fakültesi, Radyoloji Anabilim Dalı, Adana, Turkey,
4 Çukurova Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, Adana, Turkey.

ÖZET

Yüksek doz lipozomal amfoterisin B ile kür sağlanan çocukluk çağı invaziv mukormikozis

Pulmoner mukormikozis medikal tedavisinin temel dayanışık amfoterisin B olup, optimal doz konusunda henüz bir fikir birliği bulunmaktadır. Bu yüzden pulmoner mukormikozis gelişen akut lenfblastik lösemili bir çocuğun 45 haftalık sürede toplam 42.55 g lipozomal amfoterisin B kullanılarak başarı ile tedavi edildiği sunulmaktadır. Tibbi literatürde bu olgu çocukluk çağıda en yüksek dozda lipozomal amfoterisin B' nin başarıyla kullanıldığı ilk olgudur.

Anahtar Kelimeler: Lipozomal amfoterisin B, invaziv pulmoner mantar infeksiyonu, çocukluk çağı.

SUMMARY

Pediatric invasive mucormycosis cured with high dose liposomal amphotericin B

Fatih ERBEY1, Emine KOCABAŞ2, Ibrahim BAYRAM1, Süreyya SOYUPAK3, Derya GÜMÜRDÜLÜ4, Atila TANYELİ1

1 Division of Pediatric Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey,
2 Division of Pediatric Infectious, Faculty of Medicine, Cukurova University, Adana, Turkey,
3 Department of Radiology, Faculty of Medicine, Cukurova University, Adana, Turkey,
4 Department of Pathology, Faculty of Medicine, Cukurova University, Adana, Turkey.

Amphotericin B remains the mainstay medical treatment of pulmonary mucormycosis. Optimal dose is not defined. We described a case of pulmonary mucormycosis, which had been treated with 42.55 g (during to 45 weeks) liposomal am-
INTRODUCTION

Mucormycosis is the third most common invasive fungal infection after aspergillosis and candidiasis (1,2). It represents 8.3-13% of all fungal infections encountered during the autopsy of leukemia, lymphoma patients (3,4). Major forms of infection are, rhino-orbito-cerebral, pulmonary, disseminated, cutaneous, and gastrointestinal. Mucormycosis occurs most frequently in patients with ketoacidotic diabetes, acute leukemia or lymphoma who are neutropenic, and in transplanted patients receiving immunosuppressive treatment (5-7). Amphotericin B is used in the medical treatment of mucor for 2 or 3 months at a dose of 1-3 mg/kg/day (8). The dose should be initiated as at least 5 mg/kg/day if an invasive pulmonary fungal infection is suspected, and it should be increased according to the patient response. Here we describe a case of pulmonary mucormycosis which had been treated with 42.55 g (during to 45 weeks) lyposomal amphotericin B. In medical literature this case is one of the highest doses of lyposomal amphotericin B administered to a pediatric patient.

CASE REPORT

A 9-years-old male patient followed up with the diagnosis of acute lymphoblastic leukemia-L1 (ALL-L1). The patient was admitted with complaints of fever and swelling of the cheek on the 8th month of his induction chemotherapy (BFM, TRALL-2000). On his physical examination it was determined that he had oral aphthous lesions and swelling of one cheek. Lung auscultation findings and examinations of other systems proved normal. He received 10 mg/m²/day dexamethasone, 1.5 mg/m² vincristine once a week, 30 mg/m² doxorubicin once a week and 10.000 U/m ² L-asparaginase for 4 days within the last month. Laboratory results of the patient were: total white blood cell (WBC) count 800/mm³, absolute neutrophile count (ANC) 200/mm³, Hct: 25%, thrombocytes 55.000/mm³. Level of Na was 138 mmol/L, K 4.0 mmol/L, BUN 15 mg/dL, Cr 0.8 mg/dL, ALT 38 U/L, AST 42 U/L, serum reactive protein (CRP) 181 mg/L, and procalcitonin (PCT) 0.89 ng/mL. Meropenem was initiated according to the febrile neutropenia (FEN) protocol. Vancomycin was added to the treatment on the 3rd day of hospitalization since fever did not decrease (38.5°C). Maxillofacial tomography of the patient showed thick and aseptate hyphae after staining with Gomori-Methanamine-Silver stain (Figure 1). Thorax tomography was obtained. Several and various, patchy, nodular opacities with tendency to become peripheral were noted in the lung parenchyma (Figure 2). This image, radiologically conformed to mucormycosis. Amphotericin B deoxycholate therapy was stopped on day 14 and lyposomal amphotericin B (AmBisome) at a dose of 5 mg/kg/day was started. The patient was followed up with his clinic and thorax tomography. Intermittent bone marrow aspirations were performed and no active chemotherapies were administered during the period of remission. The thorax tomography obtained on day 73 of the therapy showed progression in the number and size of the lesions compared to the results of the tomography taken on day 40. Meanwhile the patient had no complaints including fever and cough. Auscultation revealed coarse crackles in the lungs. Laboratory findings of the patient were: WBC co-

Key Words: Liposomal amphotericin B, invasive pulmonary fungal infection, childhood.
unt 8800/mm³, ANC 4800/mm³, Hct: 29%, thrombocytes 185,000/mm³. Level of Na was 136 mmol/L, K 3.6 mmol/L, BUN 11 mg/dL, Cr 0.5 mg/dL, ALT 28 UI/L, AST 40 UI/L, CRP 21 mg/L, and PCT 0.15 ng/mL. The dose of liposomal amphotericin B was gradually increased up to 10 mg/kg. Maintenance chemotherapy (6-mercaptopurin 50 mg/m²/day and methotrexate 20 mg/m²/week) was initiated at half dose at week 20 of liposomal amphotericin B therapy for the risk of a possible ALL relapse. The total dose was attained one month after the start of the maintenance chemotherapy. However 2 weeks later, the patient began to cough and coarse crackles were auscultated in the lungs. Maintenance chemotherapy was stopped and ceftazidime + amikacin were added to liposomal amphotericin B therapy when WBC count became 2000/mm³, and ANC decreased to 200/mm³. Ceftazidime + amikacin therapy was completed to 14 days and then stopped, the neutropenia of the patient lasted 6 days and auscultation findings improved. Thorax tomography obtained in this period showed no changes in the number and size of the lesions. The patient had no additional complaints during the continuation of liposomal amphotericin B therapy. Thorax tomography obtained at week 45 of the therapy showed that lesions had disappeared completely and thus liposomal amphotericin B therapy was discontinued. Patient received a total of 42.55 g of liposomal amphotericin B therapy over a 45-week period.

No side effects associated with liposomal amphotericin B were determined during this period. Parenchymal lesions observed previously had disappeared in the thorax tomography of the patient that was obtained 3 months later (Figure 3). The patient is still followed up by our department and is receiving maintenance chemotherapy for ALL since the last 18 months.

**DISCUSSION**

Mucormycosis is a rare fungal infection that affects almost all immunocompromised patients. Pulmonary is the second most common involvement after rhinoencebral disease. Leukemia and lymphoma are major risk factors for mucormycosis. The diagnosis of mucormycosis is particularly difficult in immunocompromised patients. Even in the presence of hematogenous dissemination of fungi, blood cultures are negative (9). Therefore, tissue biopsy and histologic identification of fungi remain the gold standard of diagnosis. But the diagnosis is often made after death (3). Prognosis is poor and overall mortality is high (5,7). Our patient had major risk factors for the development of mucor including acute leukemia, neutropenia, and had received intensive chemotherapy and the diagnosis was established by the debridement of black plaques in the palate with tendency for necrosis and histopathological examination of the debridement material.

Figure 2. There are several, patchy nodular infiltrative opacities of variable sizes with tendency to become peripheral in both lung parenchymas.
Pulmonary mucormycosis, is the second most common site of involvement of mucorales infection. Inhalation of spores is the primary route of infection. Patients with leukaemia, lymphoma and severe neutropenia remain at greater risk of developing pulmonary mucormycosis compared to other forms (1,6). Patients can show symptoms of cough, fever, haemoptysis and pleuritic chest pain (4,7). Radiological findings include infiltrate, wedge-shaped consolidation, nodule, cavitation, mycetoma, lobar collapse and, rarely pleural effusion (1,4,7). The establishment of mucor in the debri- dement material obtained from the palate of our patient, the development of respiratory system symptoms despite the administration of a broad spectrum antibiotics and the observation of several, various, parenchy- mal patchy nodular opacities with a tendency to become peripheral in thorax tomography, suggested that this pathology was most probably pulmonary mucormycosis. However, pulmonary biopsy could not be performed due to the poor general condition of the patient as well as the wide dispersion of the lesions.

Therapy of mucormycosis is based on three approaches: rapid control of the patient’s underlying predisposing condition, antifungal therapy and surgical debridement. Tedder et al. in a review of 255 cases of pulmonary mucormycosis, who reported that the mortality rate was significantly lower for patients who underwent surgery than for those who received medical treatment only (9.4% vs. 50%, p = 0.01) (10). We were able to perform debridement from only the palate lesions of our patient, and could not perform surgical debride- ment from the pulmonary lesions for their wide dispersion.

Amphotericin B remains the mainstay medical treatment of pulmonary mucormycosis. Optimal dose is not defined. Generally dose of amphotericin B, 1-3 mg/kg/day, and minimum of 6 weeks of treatment has been recommended (8,11). Ringden et al. found lung tissue concentrations of amphotericin B to be lower than those in other tissues, suggesting that pulmonary fungal infections may require higher dosage of amphotericin B (12). The use of high doses of amphotericin B has been correlated with a good prognosis (5). Therefore, when an invasive fungal infection is suspected it should be started at a minimum dose of 5 mg/kg/day and increased according to the patient response. Cagatay et al. have reported that they succeeded curing a 31 years old male diabetic patient with the administra- tion of a total of 32 g of liposomal amphotericin B for 6 months (13). Donado-Una et al. treated a pulmonary mucormycosis infection in a 67 years old male diabetic patient with a total of 28.7 g of liposomal ampho- tericin B (11). Maury et al. on the other hand, achieved success in the treatment of a 3 years old ALL patient who had developed disseminated mucormycosis with a total of 27 g of liposomal amphotericin B (14). Mondy
et al. also treated a 50 years old, female diabetic patient with rhinocerebral mucormycosis infection with cumulative 126.3 g of amphotericin B lipid complex administered intermittently over a period of 16 months (15). Our patient is the first pediatric case in medical literature that was diagnosed with childhood invasive mucor infection and successfully treated with cumulative 42.55 g of lyposomal amphotericin B over a period of 45 weeks. The patient tolerated lyposomal amphotericin B treatment well. Fever, chills, nausea, or renal dysfunction was not observed at any time during the therapy. Low dose oral potassium supplementation was used to preserve a normal serum level.

Consequently, a pediatric ALL case with very high mortality invasive pulmonary mucormycosis infection was successfully treated with a high dose lyposomal amphotericin B. This is the highest dose administered in medical history in the pediatric age group.

**CONFLICT of INTEREST**

None declared.

**REFERENCES**